Qihan Biotech Applies Genome Editing to Create Allogenic Stem Cells
October 15, 2020 at 05:38 AM EDT
Qihan Biotech, a Hangzhou company applying genome editing to cell therapies and organ transplantation, has started a program to develop human stem cells with reduced immunogenicity. If successful, the cells will have the potential to be universal, allogeneic therapies that could be administered without (or at lower levels of) immunosuppressive drugs. Qihan said it is working with a leading stem cell company on the project, but did not disclose the company's name. More details.... Share this with colleagues: // //